Völler M - Search Results

1

The genes for the calcium-dependent cell adhesion molecules P- and E-cadherin are tandemly arranged in the human genome.

Bussemakers MJ, van Bokhoven A, Völler M, Smit FP, Schalken JA. Bussemakers MJ, et al. Among authors: voller m. Biochem Biophys Res Commun. 1994 Sep 15;203(2):1291-4. doi: 10.1006/bbrc.1994.2322. Biochem Biophys Res Commun. 1994. PMID: 8093046

2

Smoothelin expression characteristics: development of a smooth muscle cell in vitro system and identification of a vascular variant.

van Eys GJ, Völler MC, Timmer ED, Wehrens XH, Small JV, Schalken JA, Ramaekers FC, van der Loop FT. van Eys GJ, et al. Among authors: voller mc. Cell Struct Funct. 1997 Feb;22(1):65-72. doi: 10.1247/csf.22.65. Cell Struct Funct. 1997. PMID: 9113392 Free article.

3

Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.

Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS. Span PN, et al. Among authors: voller mc. J Urol. 1999 Jan;161(1):332-7. J Urol. 1999. PMID: 10037433 Clinical Trial.

4

In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.

Guzmán-Ramírez N, Völler M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG. Guzmán-Ramírez N, et al. Among authors: voller m. Prostate. 2009 Nov 1;69(15):1683-93. doi: 10.1002/pros.21018. Prostate. 2009. PMID: 19644960

5

Differential regulation of human alpha1-adrenoceptor subtypes.

Yang M, Ruan J, Voller M, Schalken J, Michel MC. Yang M, et al. Among authors: voller m. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):439-46. doi: 10.1007/pl00005373. Naunyn Schmiedebergs Arch Pharmacol. 1999. PMID: 10431753

6

hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.

Kogan I, Goldfinger N, Milyavsky M, Cohen M, Shats I, Dobler G, Klocker H, Wasylyk B, Voller M, Aalders T, Schalken JA, Oren M, Rotter V. Kogan I, et al. Among authors: voller m. Cancer Res. 2006 Apr 1;66(7):3531-40. doi: 10.1158/0008-5472.CAN-05-2183. Cancer Res. 2006. PMID: 16585177

7

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.

Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Völler MC, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PF. Bleumer I, et al. Among authors: voller mc. J Urol. 2006 Jan;175(1):57-62. doi: 10.1016/S0022-5347(05)00040-6. J Urol. 2006. PMID: 16406869 Clinical Trial.

8

Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells.

Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, De Weijer K, Mulders PF, Oosterwijk E. Bleumer I, et al. Among authors: voller mc. J Immunother. 2007 Jan;30(1):116-22. doi: 10.1097/01.cji.0000211318.22902.ec. J Immunother. 2007. PMID: 17198090 Clinical Trial.

9

The role of protein tyrosine phosphatases in density-dependent growth control of normal rat kidney cells.

Rijksen G, Völler MC, van Zoelen EJ. Rijksen G, et al. Among authors: voller mc. FEBS Lett. 1993 May 3;322(1):83-7. doi: 10.1016/0014-5793(93)81117-i. FEBS Lett. 1993. PMID: 8482374 Free article.

10

Orthovanadate both mimics and antagonizes the transforming growth factor beta action on normal rat kidney cells.

Rijksen G, Völler MC, Van Zoelen EJ. Rijksen G, et al. Among authors: voller mc. J Cell Physiol. 1993 Feb;154(2):393-401. doi: 10.1002/jcp.1041540223. J Cell Physiol. 1993. PMID: 8425920

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters